Massive Bio Inc., a private artificial intelligence-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and Fort Myers-based NeoGenomics Inc., a provider of cancer-focused genetic testing services and global oncology contract research services, announced a collaboration with the goal of accelerating the development of new cancer therapies. NeoGenomics will identify patients in real-time who may be eligible for clinical trials based on biomarker status. Following initial contact and outreach provided directly from NeoGenomics to the treating physician, Massive Bio will help obtain patient consent and expedite additional screening and potential enrollment. Company officials said this partnership will help to quickly identify patients eligible for clinical trials and help patients and providers make an informed decision regarding their potential treatment avenue.